These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 22493727

  • 1. Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats.
    Lim S, Choi SH, Shin H, Cho BJ, Park HS, Ahn BY, Kang SM, Yoon JW, Jang HC, Kim YB, Park KS.
    PLoS One; 2012; 7(4):e35007. PubMed ID: 22493727
    [Abstract] [Full Text] [Related]

  • 2. Naringenin inhibits angiotensin II-induced vascular smooth muscle cells proliferation and migration and decreases neointimal hyperplasia in balloon injured rat carotid arteries through suppressing oxidative stress.
    Xu C, Chen J, Zhang J, Hu X, Zhou X, Lu Z, Jiang H.
    Biol Pharm Bull; 2013; 36(10):1549-55. PubMed ID: 23912743
    [Abstract] [Full Text] [Related]

  • 3. Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats.
    Takai S, Sakonjo H, Jin D.
    J Pharmacol Sci; 2014; 125(4):386-93. PubMed ID: 25030743
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Differential effects of trimetazidine on vascular smooth muscle cell and endothelial cell in response to carotid artery balloon injury in diabetic rats.
    Yoon JW, Cho BJ, Park HS, Kang SM, Choi SH, Jang HC, Shin H, Lee MJ, Kim YB, Park KS, Lim S.
    Int J Cardiol; 2013 Jul 15; 167(1):126-33. PubMed ID: 22240760
    [Abstract] [Full Text] [Related]

  • 6. Attenuation of carotid neointimal formation after direct delivery of a recombinant adenovirus expressing glucagon-like peptide-1 in diabetic rats.
    Lim S, Lee GY, Park HS, Lee DH, Tae Jung O, Kyoung Min K, Kim YB, Jun HS, Hak Chul J, Park KS.
    Cardiovasc Res; 2017 Feb 15; 113(2):183-194. PubMed ID: 27702762
    [Abstract] [Full Text] [Related]

  • 7. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney.
    Joo KW, Kim S, Ahn SY, Chin HJ, Chae DW, Lee J, Han JS, Na KY.
    BMC Nephrol; 2013 Apr 27; 14():98. PubMed ID: 23621921
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cilostazol inhibits high glucose- and angiotensin II-induced type 1 plasminogen activator inhibitor expression in artery wall and neointimal region after vascular injury.
    Lee KM, Lee HJ, Kim MK, Kim HS, Jung GS, Hur SH, Kim HT, Cho WH, Kim JG, Kim BW, Lim JO, Choi HS, Lee KU, Park KG, Lee IK.
    Atherosclerosis; 2009 Dec 27; 207(2):391-8. PubMed ID: 19586629
    [Abstract] [Full Text] [Related]

  • 10. N-acetylcysteine inhibited nuclear factor-kappaB expression and the intimal hyperplasia in rat carotid arterial injury.
    Hayashi K, Takahata H, Kitagawa N, Kitange G, Kaminogo M, Shibata S.
    Neurol Res; 2001 Oct 27; 23(7):731-8. PubMed ID: 11680513
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.
    Fadini GP, Boscaro E, Albiero M, Menegazzo L, Frison V, de Kreutzenberg S, Agostini C, Tiengo A, Avogaro A.
    Diabetes Care; 2010 Jul 27; 33(7):1607-9. PubMed ID: 20357375
    [Abstract] [Full Text] [Related]

  • 14. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.
    Matsubara J, Sugiyama S, Sugamura K, Nakamura T, Fujiwara Y, Akiyama E, Kurokawa H, Nozaki T, Ohba K, Konishi M, Maeda H, Izumiya Y, Kaikita K, Sumida H, Jinnouchi H, Matsui K, Kim-Mitsuyama S, Takeya M, Ogawa H.
    J Am Coll Cardiol; 2012 Jan 17; 59(3):265-76. PubMed ID: 22240132
    [Abstract] [Full Text] [Related]

  • 15. Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells.
    Huang CY, Shih CM, Tsao NW, Lin YW, Huang PH, Wu SC, Lee AW, Kao YT, Chang NC, Nakagami H, Morishita R, Ou KL, Hou WC, Lin CY, Shyu KG, Lin FY.
    Br J Pharmacol; 2012 Dec 17; 167(7):1506-19. PubMed ID: 22788747
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
    Aaboe K, Knop FK, Vilsbøll T, Deacon CF, Holst JJ, Madsbad S, Krarup T.
    Diabetes Obes Metab; 2010 Apr 17; 12(4):323-33. PubMed ID: 20380653
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients.
    Satoh-Asahara N, Sasaki Y, Wada H, Tochiya M, Iguchi A, Nakagawachi R, Odori S, Kono S, Hasegawa K, Shimatsu A.
    Metabolism; 2013 Mar 17; 62(3):347-51. PubMed ID: 23062489
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.